Recursion Pharmaceuticals Inc (NASDAQ:RXRX) shares moved higher Wednesday after JPMorgan upgraded the stock to Overweight ...

Recursion Pharmaceuticals (RXRX) just delivered encouraging Phase 1b/2 TUPELO data for its FAP drug candidate REC-4881, and that clinical update has quickly reshaped how both Wall Street and ...

Recursion Pharmaceuticals, Inc. is rated a Sell due to cash burn, Q3 net loss of $162.25M and operational trends. Learn more ...

Najat Khan, PhD, unpacks realistic timelines for AI-based drugs to make clinical impact and her priorities for Recursion as incoming CEO.

If language is what makes us human, what does it mean now that large language models have gained “metalinguistic” abilities?

The native just-in-time compiler in Python 3.15 can speed up code by as much as 20% or more, although it’s still experimental ...

AI can help design AI systems: automating architecture choices, discovering algorithms, and optimizing hardware ...

With the popularity of AI coding tools rising among some software developers, their adoption has begun to touch every aspect ...

Wondering if Recursion Pharmaceuticals at around $4.83 is a beaten down bargain or a value trap? This breakdown walks through what the current market price is really implying. The stock has bounced ...

Innovation fails when every pilot starts from scratch; the chassis approach shows how to move fast with vendors while keeping ...

REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden and a 43% median ...

Here are seven biopharma-related trends for 2026 that have emerged from GEN interviews with experts and other industry stakeholders, and from reviews of reports and public statements.